Katy Rezvani is a Reader in the department of haematology. She is the clinical lead in allogeneic stem cell transplantation and clinical director of the Jacie accredited GMP cellular facility.
Dr. Rezvani obtained her medical degree from University College London and completed her training in haematology and stem cell transplantation in London. In 2001 she was awarded an LRF/NHLBI fellowship to pursue research in transplantation immunology at the National Institutes of Health, Bethesda, USA. She continued with her research as a senior research fellow at the NIH until January 2008 when she was awarded a HEFCE clinical senior lectureship to start her position at Imperial College.
Dr. Rezvani has an active laboratory based program and is a mentor to 5 Ph.D. students and clinical research fellows. Her main research interest is in translational tumour and transplant immunology. Her research projects include strategies to enhance post-transplant immune reconstitution, with a strong focus on the role of T, B and Natural Killer (NK) cells in graft-versus-host-disease (GVHD) and graft vs. leukaemia (GVL) effects.
Dr Rezvani has also set up a translational programme in immunotherapy and developed novel protocols for the manufacture of GMP grade cellular products including viral specific T cells and NK cells for use in clinical trials to improve patient outcome following allogeneic stem cell transplantation. Her laboratory studies in immune responses to leukaemia have led to the initiation of a number of clinical trials of vaccination against tumour antigens including PR1 and WT1 in patients with myeloid malignancies.
et al., 2013, Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT, Bone Marrow Transplantation, Vol:48, ISSN:0268-3369, Pages:1324-1328
et al., 2013, Donor lymphocyte collections using the spectra Optia MNC version 5, Transfusion and Apheresis Science, Vol:48, ISSN:1473-0502, Pages:171-171
et al., 2013, Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies, Blood, Vol:121, ISSN:0006-4971, Pages:2739-2742
et al., 2013, Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling, Blood, Vol:122, ISSN:0006-4971, Pages:227-238
et al., 2012, Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia, Blood, Vol:120, ISSN:0006-4971, Pages:697-698